Company: IOBT
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047744
Chunk: 141

Company: IO Biotech, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 141
---
86,083
    )

    Net loss attributable to common shareholders

    (95,491
    )

    (86,083
    )

    Net loss per common share, basic and diluted
     
    $
    (1.45
    )
     
    $
    (1.98
    )

    Weighted-average number of shares used in computing net loss per common share, basic and diluted

    65,880,914

    43,539,976

    Other comprehensive loss

    Net loss
     
    $
    (95,491
    )
     
    $
    (86,083
    )

    Foreign currency translation

    2,818

    472

    Total comprehensive loss
     
    $
    (92,673
    )
     
    $
    (85,611
    )

See accompanying notes to the consolidated financial statements. 

144

IO BIOTECH, INC. 

Consolidated Statements of Stockholders’ Equity 

(In thousands, except share amounts) 

    Common Stock

    AdditionalPaid-In

    Accumulated OtherComprehensive

    Accumulated

    TotalStockholders’

    Shares

    Amount

    Capital

    Loss

    Deficit

    Equity

    Balance, January 1, 2023

    28,815,267

    29

    326,705

    (10,141
    )

    (177,739
    )

    138,854

    Equity-based compensation

    —

    —

    8,059

    —

    —

    8,059

    Foreign currency translation

    —

    —

    —

    472

    —

    472

    Issuance of common shares and warrants in private placement, net of issuance costs of $3,198

    37,065,647

    37

    71,823

    —

    71,860

    Net loss

    —

    —

    —

    —

    (86,083
    )

    (86,083
    )

    Balance, December 31, 2023

    65,880,914

    $
    66

    $
    406,587

    $
    (9,669
    )
     
    $
    (263,822
    )
     
    $
    133,162

    Equity-based compensation

    —

    —

    6,